Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal Hypertension
Changpeng Zhu(Shanghai Changzheng Hospital), Wei‐Fen Xie(State Council of the People's Republic of China), Jordi Gracia‐Sancho(Institut d'Investigacions Biomèdiques de Barcelona), Zoe Boyer‐Díaz, Peio Aristu-Zabalza(Departament de Salut), Xin Zhang(Ministry of Education of the People's Republic of China), Shaohua Song(Shanghai Jiao Tong University), Hai-Lin Xiong(Shanghai Changzheng Hospital), Keqi Wang(Shanghai Changzheng Hospital), Cheng Luo(Chinese Academy of Sciences), Ji-Feng Feng(Shanghai Changzheng Hospital), Weihua Dong(Shanghai Changzheng Hospital), Shuqing Liu(Chengdu University of Traditional Chinese Medicine), Wansheng Chen(Second Military Medical University)
Cited by 12
Related Papers
Chinese Consensus Report on Family-Based<i>Helicobacter pylori</i>Infection Control and Management (2021 Edition)
|Gut|2021|183
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
|Journal of Hepatology|2020|163
An HNF1α-regulated feedback circuit modulates hepatic fibrogenesis via the crosstalk between hepatocytes and hepatic stellate cells
|Cell Research|2015|82
The HNF1α-regulated lncRNA HNF1A-AS1 reverses the malignancy of hepatocellular carcinoma by enhancing the phosphatase activity of SHP-1
|Molecular Cancer|2018|69
Tanreqing Inhibits LPS-Induced Acute Lung Injury In Vivo and In Vitro Through Downregulating STING Signaling Pathway
|Frontiers in Pharmacology|2021|45